Drug Discovery - Research & Development

CNS Pharmaceuticals acquired worldwide rights for brain cancer drug from Houston Pharmaceuticals

CNS Pharmaceuticals, a biotechnology company specializing in the development of novel treatments for brain tumors, completed an agreement with Houston Pharmaceuticals, Inc. ("HPI") to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as Berubicin.

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

US-based Dicerna Pharmaceuticals and Novo Nordisk have signed a deal worth up to around $607m to discover and develop drugs for liver-related cardio-metabolic diseases.

Aerie Pharmaceuticals agrees to acquire Avizorex Pharma

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, announced the signing of an agreement (the “Agreement”) for the acquisition of Avizorex Pharma, S.L. (“AVX Pharma” or “AVX”), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.

Alkermes to buy Rodin Therapeutics for up to $950m

Alkermes has signed an agreement to acquire biopharmaceutical company Rodin Therapeutics in a deal valued at around $950m.

Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal

Roche has agreed to acquire US-based clinical-stage biotechnology company Promedior in a deal valued at around $1.39bn.

EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform

EpicentRx, a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has raised a $35 million Series D financing using the Silicon Valley based life-science focused investment bank, Biotech Alliances International.

Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics

Finch Therapeutics Group, Inc. (“Finch”) and Takeda Pharmaceutical Company Limited (“Takeda”; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finch’s Human-First Discovery platform.

RDD Pharma signs LOI to acquire Naia Rare Diseases

RDD Pharma, a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent (LOI) to acquire Naia Rare Diseases ("Naia"), a biopharmaceutical company developing drugs for Short Bowel Syndrome ("SBS") and other rare gastrointestinal diseases.

Merck to acquire Calporta Therapeutics for $576m

COI Pharmaceuticals announced that Merck has agreed to acquire Calporta Therapeutics in a deal valued at around $576m.